Invasive mucinous adenocarcinoma of the lung: integrating molecular landscape, imaging phenotypes, and translational therapeutic strategies Authors: Zihan Wang, Jiashuo Wang, Shiqi Liu, Shi Zong, Xiwen Wang Published: 2026 ABSTRACT AbstractInvasive mucinous adenocarcinoma (IMA) of the lung is an uncommon but clinically important subtype of lung adenocarcinoma with distinctive radiologic, histopathologic, and molecular features. Its indolent symptoms, mucin-rich growth pattern, and frequent pneumonia-like or multifocal presentation can obscure early diagnosis and complicate distinction from infection, synchronous primary tumors, and intrapulmonary spread. This review integrates current evidence on the clinical course, imaging phenotypes, diagnostic workflow, histopathologic features, molecular alterations, tumor immune microenvironment, and treatment response patterns of IMA. Emphasis is placed on the relationship between radiologic appearance and underlying mucinous pathology, the clinical significance of spread through air spaces (STAS), and the need for adequate tissue sampling and comprehensive molecular profiling. Compared with non-mucinous lung adenocarcinoma, IMA is enriched for KRAS mutations and selected fusion or receptor alterations, whereas canonical EGFR mutations are less frequent. These biological differences help explain why treatment strategies extrapolated from broader non-small cell lung cancer (NSCLC) populations may be insufficient, particularly for multifocal, pneumonic-type, or advanced disease. Although surgery can provide favorable outcomes in localized disease, systemic therapy remains challenging, and the role of immunotherapy requires further clarification. Future progress will depend on integrated imaging-pathology-genomic models, prospective IMA-specific cohorts, and translational studies aimed at refining classification and developing individualized therapeutic strategies.Keywords: Invasive mucinous adenocarcinoma (IMA), Kirsten rat sarcoma viral homolog mutation (KRAS mutation), neuregulin 1 fusion, spread through air spaces (STAS), immune microenvironment Introduction Invasive mucinous adenocarcinoma (IMA) of the lung is regarded as a distinct but uncommon lung adenocarcinoma subtype characterized by excessive mucin production. In the 2015 World Health Organization (WHO) classification of lung tumors, the entity previously termed mucinous bronchioloalveolar carcinoma was reclassified as IMA (1). Epidemiologic data suggest that IMA accounts for approximately 3–10% of lung adenocarcinomas (2). It is unknown whether the incidence of IMA is increasing along with that of adenocarcinomas generally (3). IMA often mimics pneumonia clinically and radiologically; its low incidence often contributing to misdiagnosis and delayed specific treatment (4,5). Clinically, symptoms are nonspecific; patients may report chronic cough, sputum production, or recurrent infection-like episodes. On imaging, IMA may present as diffuse consolidation with a pneumonia-like distribution. Propensity for intrapulmonary dissemination along the airways is a defining characteristic of IMA. Clinically, this behavior manifests as aerogenous spread and corresponds histologically to spread through air spaces (STAS) (6). STAS is defined by the presence of tumor cells within alveolar air spaces beyond the main tumor margin, indicating that malignant cells can detach from the primary lesion and disseminate along alveoli and the bronchiolar tree. This process may generate satellite lesions within the same segment, the ipsilateral lobe, or even the contralateral lung (7). This leads to IMA frequently presenting with multiple mucinous nodules or patchy opacities in one or both lungs. This multifocal appearance complicates differential diagnosis; with possible synchronous multicentric tumors or intrapulmonary spread from a single primary lesion. Diagnosis relies on a multidisciplinary approach integrating the results of chest radiology and computed tomography (CT) and 18F-fluoro-deoxyglucose (FDG) positron emission tomography (PET) scans with tissue pathology. Transbronchial biopsies, with or without endobronchial ultrasound, may be difficult to target as lesions are often peripheral; percutaneous CT-guided needle or surgical histopathologic specimens, interpreted in the light of imaging findings, are required for definitive diagnosis of IMA, grading and staging (with subsequent molecular examination for specific mutations or biomarkers). Current management of IMA is largely extrapolated from non-mucinous adenocarcinoma (NMA); however, this approach is often suboptimal. IMA grading, staging and prognosis remain controversial with treatment options including surgery, chemotherapy, radiotherapy, targeted treatment, immunotherapy and palliative care (2). IMA is associated with high recurrence rates and a lack of effective standardized treatment options. Canonical epidermal growth factor receptor (EGFR) mutations are rare in IMA (<5%), whereas specific Kirsten rat sarcoma viral homolog (KRAS) mutations are substantially more prevalent. Consequently, many targeted therapies effective in non-mucinous lung adenocarcinoma have limited efficacy in IMA (8-10). In addition, IMA often responds poorly to immunotherapy and is frequently described as an immune-cold tumor, further limiting the benefits of current treatment modalities (11). Therefore, developing precise, stratified therapeutic strategies that target IMA-specific biology has become a clinical imperative. Against this background, we aim to provide a comprehensive overview of recent advances in imaging, histopathologic, and molecular perspectives of IMA. We first describe the demographic characteristics and natural history of IMA and compare them with those of NMA. We then discuss the distinctive imaging features of IMA and histopathologic correlations. Next, we review diagnostic workflow and tissue-acquisition strategies, followed by histopathologic features, immunophenotype, STAS, and molecular alterations. In each section, we aim to emphasize systematic differences between IMA and lung adenocarcinoma in general and discuss their implications for diagnosis and prognosis. In the treatment section, we review responses to surgery, chemotherapy, targeted therapy, and immunotherapy, together with proposed mechanisms, and summarize emerging approaches and ongoing clinical trials. Finally, we aim to highlight key controversies and knowledge gaps and discuss how future single-cell, multi-omics, and multidisciplinary research may deepen mechanistic understanding, improve clinical management, and inform updates to practice guidelines. Clinical characteristics and natural course of IMA Demographic characteristics Patients with IMA exhibit demographic characteristics that differ from those of NMA. Most studies report an older age at diagnosis of IMA; typically patients are middle-aged to older adults, with a slight female predominance. A recent large cohort study of 312 IMA cases reported a median age at diagnosis >60 years and a modest female predominance (the female-to-male ratio was 1.38:1.0) (12). Similarly, an analysis of 72 IMA cases reported a median age of 61 years and a female-to-male ratio of approximately 1.25:1.0 (13). IMA is less strongly associated with tobacco smoking than other lung cancer subtypes, such as squamous cell carcinoma. A substantial proportion of patients are never-smokers or have only minimal smoking history. This clinical pattern suggests that IMA pathogenesis may be partly independent of smoking-related carcinogenesis (14,15). Limited evidence is available regarding other etiological factors such as exposure to asbestos, radon, heavy metals or air pollution. The importance of genetic predisposition (family history), and pre-existing lung damage remains unclear. Anatomically, IMA preferentially involves the lower lobes. Surveillance, Epidemiology, and End Results (SEER) analyses suggest that IMA is more common in the bilateral lower lobes and typically presents as an isolated peripheral lesion at diagnosis (16). Histopathologically, IMA is typically moderately to well differentiated. Tumors are composed predominantly of mucin-producing columnar or goblet cells, resulting in relatively mild cytologic atypia and a characteristically bland microscopic appearance. However, the high degree of differentiation and abundant mucin may cause early imaging findings to resemble indolent lesions e.g., ground-glass (GG) nodules, potentially masking invasive potential (17). Symptoms and clinical presentation IMA typically presents with insidious onset and nonspecific clinical manifestations. Many patients experience only mild chronic cough and sputum production, which may be interpreted as chronic bronchitis or bronchiectasis, before one or more lesions are detected on imaging, then often misinterpreted as pneumonia or resulting from previous infection (18). Abundant mucin secretion by tumor cells, leads some patients to produce large volumes of clear or white, sputum (19). Clinically, IMA often presents as pneumonia-like consolidation usually initially treated with antibiotics; however, therapeutic response is usually poor. More challenging are cases that demonstrate transient radiologic improvement followed by subsequent progression or recurrence (10,20). Unlike infectious pneumonia, fever is uncommon in IMA: accompanying leukocytosis, and elevated C-reactive protein levels make an infectious etiology more likely than malignancy. A multicenter study comparing IMA presenting with pneumonia-mimicking consolidation and infectious pneumonia showed that patients with IMA rarely exhibited fever or significant inflammatory markers, whereas patients with infection frequently had both (3). Accordingly, clinicians should consider the possibility of IMA, and pursue histopathologic evaluation at an early stage, in patients with recurrent or persistent consolidation in the same pulmonary region without clear evidence of infection. STAS and multifocal disease As previously mentioned, STAS results in multifocal pulmonary involvement and is strongly associated with increased risk of recurrence (21) and significantly shorter progression-free survival (PFS) following surgical resection in IMA (22). A recent systematic review and meta-analysis discussed how this tendency towards multifocal involvement and airborne dissemination challenges the applicability of traditional staging systems-primarily designed for solitary tumors-thereby complicating clinical management and treatment decisions. In univariate analysis, gender, tumor, node, metastasis (TNM) classification stage, smoking history, lymph node metastasis, pleural metastasis, STAS, tumor size, CT findings of consolidative-type morphology, or pneumonia, and well-defined heterogeneous GG opacities were risk factors for death from IMA, while gender, age, smoking, lymph node metastasis, pathological grade, and pneumonia signs were risk factors for recurrence. However, spiculated margins were a protective factor. In multivariate analysis, smoking history, lymph node metastasis, STAS, tumor size, and pneumonia signs were found to be risk factors for death from IMA; lymph node metastasis, pathological grade, tumor size, and pneumonia signs were risk factors for recurrence (2). Tumor staging and prognosis Conventional TNM staging has limited ability to distinguish primary tumor (T) burden from intrapulmonary metastasis (M) because IMA often presents with multiple pulmonary lesions (23,24) and its prognostic performance remains controversial in IMA. Several studies report that early-stage IMA is not associated with worse outcomes than stage-matched NMA and may actually be associated with superior survival. For example, U.S. population-based data showed that patients with stages IA–IIB IMA had better overall survival than those with stage-matched NMA, potentially reflecting a tendency for IMA to remain lung-confined with fewer distant metastases (25). Similarly, a recent propensity score-matched analysis of 303 IMA and 1,212 NMA cases found no significant difference in overall survival among surgically resected, stage-matched patients. Notably, lymph node involvement was less frequent in IMA: 94% had no nodal metastasis, compared with 72% in NMA patients (16). These less aggressive features may make early-stage IMA appear indolent. However, by contrast, if IMA presents as diffuse multifocal disease, or becomes advanced, therapeutic options are limited and prognosis worsens markedly. Locally advanced or stage IV IMA often lacks effective systemic options because most driver alterations are not readily targetable and chemotherapy responses are modest. In a study by Demir et al. first-line platinum-based chemotherapy achieved an objective response rate (ORR) of ~26% and a median PFS of 8.1 months in metastatic IMA. In comparison, the small subset of patients with EGFR mutations experienced more durable responses to EGFR-targeted therapy (26). Immunotherapy outcomes are also unfavorable: KRAS-mutant IMA shows poorer responses to programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) inhibitors than NMA. A retrospective analysis reported a median PFS of 3.5 months in IMA treated with immunotherapy, compared with 8.9 months in non-IMA patients with KRAS-mutant disease (27); similar findings were also reported by Di Federico et al., who demonstrated limited efficacy of immunotherapy in mucinous histology (11). These findings underscore the poor prognosis of advanced IMA. Alternative staging approaches have been proposed for pulmonary mucinous adenocarcinoma to better capture prognostic features (25). Collectively, the clinical course of IMA appears biphasic: early, localized disease is associated with favorable outcomes, whereas advanced, diffuse disease can progress rapidly and remains difficult to treat. These observations highlight the need for staging and prognostic models tailored to IMA biology to better inform clinical decision-making. Table 1 summarizes prognostic factors and potential mechanisms in IMA. Table 1Prognostic factors in IMA and proposed mechanismsPrognostic factorImpact on prognosisPossible mechanisms/explanationsMultifocal disease (diffuse/pneumonic type disease)Multifocal or pneumonic-type disease is associated with markedly worse outcomes: advanced diffuse IMA progresses rapidly with substantially lower survival than localized solitary lesions (23,24)Frequently reflects aerogenous spread along airways; disease may remain confined to the lung, yet be difficult to completely resect (19,20,28). Conventional TNM staging may not capture multifocal tumor burden and may underestimate stage by failing to distinguish primary foci from intrapulmonary metastases (23,24)STAS statusSTAS positivity predicts higher postoperative recurrence and shorter disease-free survival (21,22)Tumor cells detach and float through alveolar spaces, potentially forming residual nests beyond grossly negative margins and causing local recurrence (19-22,29)Driver alteration status (KRAS vs. actionable drivers)Presence of actionable drivers is associated with relatively better outcomes (26,30,31). In contrast, tumors without actionable alterations have poorer outcomes due to limited effective targeted options and suboptimal immunotherapy efficacy (8-10)KRAS-driven IMA lacks established, broadly effective, targeted therapy and is often immunologically cold (weak immunotherapy responses) (8-11). Conversely, EGFR mutations or ALK fusion, enable effective targeted control of progression (26,30,31)Histologic composition (pure mucinous vs. mixed)Mixed IMA (mucinous adenocarcinoma with additional non-mucinous components) has worse prognosis than pure mucinous IMA (32,33)Mixed tumors include high-grade non-mucinous components with more aggressive biology and higher propensity for local recurrence and distant metastasis (32,33)Comorbidities (baseline health status)Severe comorbidities (e.g., chronic lung disease, cardiovascular disease) and advanced age with multiple conditions may worsen overall survivalReduced physiologic reserve and treatment tolerance can limit the feasibility of aggressive surgery or systemic therapy, thereby lowering tumor control and long-term survival probabilityTreatment modality (surgical vs. non-surgical)Patients undergoing curative resection generally fare better (28). Advanced, non-surgical patients relying on chemotherapy/immunotherapy typically have poor outcomes because of limited efficacy and short median survival (8,18,34-36)Complete surgical removal maximizes clearance and provides a potential for cure; in advanced IMA, the scarcity of effective systemic therapies makes tumor burden difficult to control. Resectability and completeness of resection are thus key determinants of prognosis (37,38)IMA, invasive mucinous adenocarcinoma; STAS, spread through air spaces; TNM, tumor-node-metastasis. Prognostic factors in IMA and proposed mechanisms IMA, invasive mucinous adenocarcinoma; STAS, spread through air spaces; TNM, tumor-node-metastasis. Radiological features Radiological phenotype framework IMA demonstrates a broad spectrum of imaging findings, with substantial overlap with inflammatory and infectious lung diseases. To improve clarity and consistency, the radiologic manifestations of IMA can be separated into two principal phenotypes: solitary-type IMA and pneumonic-type IMA, as a practical framework for clinicoradiologic interpretation. Solitary-type IMA usually presents as a discrete peripheral nodule or mass, whereas pneumonic-type IMA presents as segmental, lobar, multilobar, or diffuse consolidation or GG opacities that may mimic infectious pneumonia (37,39). However, some lesions may show mixed, transitional, or indeterminate features, such as an irregular infiltrative lesion, a dominant nodule with surrounding consolidation, or multifocal lesions that do not conform clearly to either solitary-type or pneumonic-type disease. In such cases, the radiologic lesion should be explicitly described as a mixed, atypical, or indeterminate, rather than being forced into one of the two categories. Selected CT examples illustrating the heterogeneous radiologic appearance of pathologically confirmed IMA are shown in Figure 1. Chest CT patterns of pulmonary IMA in three illustrative patients. (A,B). Patient 1 (62-year-old female was admitted with a 2-month history of cough and dyspnea). Chest CT shows an abrupt truncation of the bronchus in the posterior basal segment of the right lower lobe, with a locally irregular soft-tissue-density opacity of approximately 48 mm × 41 mm in maximal axial dimensions, adherent to the adjacent pleura, and accompanied by a small amount of ill-defined patchy shadowing in the surrounding area. (C,D) Patient 2 (63-year-old male, admitted after a pulmonary mass, was detected during the chest CT in a health checkup 3 weeks earlier, when he was seen with mild chest tightness and dyspnea). Chest CT shows an irregular mass in the anteromedial basal segment of the left lower lobe (47 mm × 35 mm in maximal axial dimensions), with mild marginal lobulation, adhesion to the adjacent interlobar pleura, a visible air bronchogram, and a small amount of patchy opacity in the distal lung parenchyma. (E,F) Patient 3 (male, 54 years old, admitted after a pulmonary mass, was detected during chest CT in an health checkup 1 month earlier, when he was seen with cough producing white mucoid sputum). Chest CT shows a mixed-density nodular lesion in the apical segment of the right upper lobe, measuring approximately 14 mm × 17 mm, with spiculated margins and small intralesional air lucencies. Corresponding mediastinal-window images are included to provide complementary anatomic and staging context rather than to demonstrate IMA-specific diagnostic features. Written informed consent was taken from all the patients. CT, computed tomography; IMA, invasive mucinous adenocarcinoma. Solitary-type IMA Solitary-type IMA is the most common radiologic presentation at diagnosis and typically appears as a discrete peripheral nodule or mass. In a study by Qi et al. including 312 patients with IMA, 80.8% presented with a regular nodule/mass pattern, whereas 13.8% had irregular infiltrative lesions and 5.4% showed large confluent pneumonic consolidation. Solid nodules are the most common attenuation pattern, followed by nodules with a halo sign. Mixed GG attenuation is less frequent, whereas pure GG opacities and cystic lucencies are uncommon (12). These findings indicate that although IMA is mucinous, solitary-type lesions may range from GG or part-solid nodules to solid masses. Typical CT features of larger solitary-type IMA include air bronchograms (visible air-filled bronchi coursing through the lesion which may reflect tumor growth along preserved alveolar structures with retained bronchial patency), lobulated margins, spiculation, pleural retraction, and occasionally intralesional lucencies. Lobulation and spiculation suggest heterogeneous tumor growth and peripheral microinvasion (12,40,41). When a dominant mass or nodule is accompanied by limited perilesional consolidation or patchy opacity, it should be described as solitary-type IMA with associated perilesional airspace change, unless the overall distribution fulfills the criteria for pneumonic-type disease. Pneumonic-type IMA and differential diagnosis Pneumonic-type IMA refers to IMA presenting as non-resolving airspace disease, typically with segmental, lobar, multilobar, or diffuse consolidation and/or GG opacity. This phenotype closely mimics infectious pneumonia and is a major cause of delayed diagnosis. Patients may receive repeated courses of antibiotics because the radiologic abnormality is initially interpreted as infection; however, lesions often persist, recur, or progress, prompting biopsy and eventual confirmation of malignancy (37). Several clinical and CT features may help distinguish pneumonic-type IMA from infectious pneumonia. Patients with pneumonic-type IMA are typically older and often lack fever or other signs of infection compared to pneumonia. On CT, they more frequently show air bronchograms, small satellite nodules, and extension across interlobar fissures (3). Lobar expansion may also be observed because of abundant intra-alveolar mucin and tumor burden, whereas infectious consolidation more commonly causes volume loss; this distinction may aid differential diagnosis. However, a single CT examination may be insufficient for definitive diagnosis, and interval follow-up imaging and histopathologic confirmation are particularly important when pneumonic IMA is suspected. Advanced and future imaging approaches PET-CT metabolic features IMA lesions typically exhibit relatively low metabolic uptake on 18F-FDG PET/CT, which can result in false-negative findings during staging. This is primarily due to the low tumor cell density in IMA, compared to solid adenocarcinomas (42). Sun et al. reported a median standardized uptake value (SUV)max of approximately 3.0 (range, 0.5–23.1) in 72 IMA patients, significantly lower than that observed in NMA. Significantly higher SUV values were reported in lesions lacking GG components, patients with clinical symptoms, advanced disease, or STAS compared to those with pure GG lesions, asymptomatic or early-stage disease. Patients with an SUVmax ≥3 exhibited worse outcomes, suggesting that a high metabolic phenotype may correlate with more aggressive disease (13). PET scans are often negative or show only faint uptake in pure GG or part-solid nodule IMA lesions. Metabolic activity may increase as the disease progresses in size or exhibits aerogenous spread. PET findings should be interpreted in conjunction with CT features, clinical presentation, and histopathologic analysis in suspected pneumonia-like IMA. Radiomics and artificial intelligence (AI) With the development of AI, radiomics and deep learning have shown considerable potential for improving the preoperative diagnosis of IMA. CT-based radiomics models combined with clinical parameters have been developed to distinguish solitary mucinous adenocarcinoma nodules from pulmonary tuberculomas, achieving area under the curve (AUC) values of 0.94–0.99 (43). Radiomics models have also been used to identify mucinous components in lung adenocarcinoma and to predict IMA with better performance than conventional imaging features (44). Furthermore, bar chart models combining CT imaging features with multiscale volumetric radiology have been developed to distinguish between IMA and NMA, achieving an AUC as high as 0.85 (45). More broadly, deep learning and radiomics based on PET/CT have been applied to predict high-grade histologic components, in lung adenocarcinomas, supporting the feasibility of noninvasive “pathologic inference” (46,47). Although these approaches remain in the research phase, they may help address the persistent challenge of preoperative IMA diagnosis. For example, AI models may flag malignant potential in suspected pneumonia cases that are unresponsive to antibiotics and demonstrate fluctuating imaging findings. In patients with confirmed lung adenocarcinoma, radiomics may also facilitate identification of occult mucinous components, thereby informing treatment selection. Development of PET ligands specifically targeting mucin labeling might have a potential role in distinguishing IMA subtypes. In summary, IMA exhibits heterogeneous imaging manifestations ranging from an isolated nodule to diffuse consolidation, mimicking lesions across the benign-malignant spectrum. Clinicians should maintain a high index of suspicion that “atypical pneumonia” may represent IMA mandating timely tissue sampling when indicated. In the future, multimodal imaging integrated with AI may improve early detection of IMA. Diagnostic workflow, tissue acquisition, and biopsy strategy Diagnostic triggers and multidisciplinary workflow Because IMA often mimics infectious pneumonia or inflammatory lung disease, its diagnosis should follow a multidisciplinary workflow that integrates clinical history, serial imaging, tissue morphology, immunophenotyping, and molecular testing. In patients with persistent or recurrent pneumonia-like consolidation, multifocal mucinous nodules, or airspace opacities that fail to resolve after appropriate anti-infective treatment, malignancy should be considered early and tissue confirmation should not be delayed. A multicenter study comparing pneumonic-type IMA with infectious pneumonia showed that careful evaluation of clinical and CT features can help distinguish these entities, supporting the need for early clinicoradiologic suspicion rather than repeated empirical treatment alone (4). Comparison of serial CT examinations is particularly important, because IMA may show transient radiologic fluctuation while continuing to progress along the airspaces. PET/CT may assist in staging and biopsy planning, but low FDG uptake does not exclude IMA, as tumor cellularity may be low and extracellular mucin may predominate. Tissue acquisition and biopsy strategy Tissue acquisition is a major diagnostic challenge in IMA. Histologically, IMA may contain abundant extracellular mucin with only scattered clusters of tumor cells, and small bronchoscopic or cytologic specimens may therefore be nondiagnostic or insufficient for ancillary testing (48-51). The biopsy approach should be selected according to the radiologic pattern, lesion distribution, and the anticipated need for molecular profiling. For peripheral nodular or mass-like lesions, CT-guided core needle biopsy can provide diagnostically useful tissue when the lesion is safely accessible. For bronchocentric, multifocal, or diffuse pneumonic-type disease, bronchoscopic tissue sampling is often attempted, mainly by transbronchial lung biopsy with radial endobronchial ultrasound, navigational guidance, or endobronchial ultrasound (EBUS) as appropriate (52,53). The term “bronchial biopsy” should be interpreted with caution in IMA, because true endobronchial tumor growth is uncommon; in most cases, the relevant procedure is transbronchial sampling of parenchymal or peribronchial disease rather than biopsy of an intraluminal bronchial mass. When lymphadenopathy is present, EBUS-guided transbronchial needle aspiration may provide staging information and material for molecular testing, although cytology specimens may still be limited by tumor fraction and nucleic acid yield (52,53). It follows that biopsy planning should not only aim to establish malignancy but also to obtain adequate material for downstream pathologic and molecular examination. Tissue adequacy for molecular testing and the role of cryobiopsy For advanced, recurrent, or unresectable IMA, tissue adequacy for molecular testing should be considered at the time of initial biopsy planning. Diagnostic sampling should aim to establish histology but also to preserve sufficient material for immunohistochemistry (IHC) and comprehensive molecular profiling of KRAS mutations, NRG1 fusions, ERBB2 alterations, and the less frequent ALK, ROS1, or NTRK fusions; all clinically relevant alterations in IMA (54,55). Close communication between pulmonologists, interventional radiologists, pathologists, and oncologists, at multidisciplinary meetings, is therefore essential. Pathologists should assess tumor cellularity, mucin content, necrosis, and the remaining unstained tissue before ordering multiple single-marker assays. When tissue is limited, a tissue-sparing strategy, such as prioritizing essential immunohistochemical markers and using a comprehensive next-generation sequencing panel, when feasible, may reduce the risk of exhausting the specimen before clinically relevant molecular information is obtained (50,51,54,55). Cryobiopsy may be considered as a complementary tissue-acquisition method in selected cases. Transbronchial cryobiopsy can obtain larger tissue samples, with better preservation of alveolar architecture, compared to conventional forceps biopsy, which may be useful when IMA is suspected but conventional bronchoscopic biopsy yields only mucin, inflammation, or scant tumor cells (56-59). Cryobiopsy may also improve the likelihood of obtaining adequate material for molecular profiling in cases requiring broad genomic testing (56-58), however, it should not be regarded as a routine procedure for all patients with suspected IMA. Its use depends on lesion location, institutional expertise, bleeding and pneumothorax risk, respiratory reserve, and the anticipated need for molecular testing (58,59). In cases in which repeated small biopsies remain nondiagnostic despite strong clinicoradiologic suspicion, surgical lung biopsy or resection may still be required to establish the diagnosis and to evaluate features such as STAS, mixed mucinous/non-mucinous components, and formal histologic grade. Overall, the diagnostic strategy for IMA should move from radiologic suspicion to adequate tissue acquisition and then to integrated pathologic and molecular interpretation. This workflow is clinically important because insufficient sampling may lead not only to delayed diagnosis but also to missed actionable alterations and suboptimal treatment selection. Histopathologic and cytologic characteristics Histopathologic features IMA has distinctive histopathologic features (60); grossly, the cut surface is typically gray-white to pale yellow, often appearing gelatinous because of abundant mucin. Microscopically, tumors are composed of well-differentiated columnar or goblet cells arranged in a single layer along alveolar walls, resembling gastrointestinal-type mucinous epithelium. The cytoplasm contains abundant neutral mucin and appears pale or vacuolated on hematoxylin and eosin staining; nuclei are basally displaced and cytologic atypia is minimal. Extracellular mucin may accumulate extensively within alveolar spaces, forming pools containing only sparse clusters of floating tumor cells. Regions of very low tumor density may be misinterpreted as mucous pneumonia, benign mucous change, or processing artifact, particularly in inadequately handled specimens (34,61). Clinico-radiologic correlation is therefore essential for accurate diagnosis. Differential diagnosis of IMA encompasses both primary pulmonary adenocarcinoma subtypes with overlapping morphology and metastatic mucinous adenocarcinomas. Among primary pulmonary tumors, colloid adenocarcinoma is characterized by large pools of extracellular mucin containing clusters of floating tumor cells, often with a cribriform or microcystic architecture, but lacks the lepidic growth pattern typical of IMA. In contrast, IMA shows lepidic proliferation of mucinous columnar or goblet cells along alveolar walls, with mucin pools confined within alveolar spaces. Papillary adenocarcinoma may contain tall columnar cells with apical mucin, mimicking IMA; however, papillary adenocarcinoma exhibits fibrovascular cores lined by neoplastic cells, whereas IMA lacks true papillary structures. Metastatic gastrointestinal mucinous adenocarcinomas and pancreatic ductal adenocarcinoma metastatic to the lung may overlap with IMA mucinous morphology and, in some cases, immunophenotypic and molecular features. Therefore, with a known or clinically suspected, extrapulmonary primary tumor, morphologic findings should be interpreted together with the clinical history, thoracoabdominal imaging, lesion distribution, and subsequent site-directed IHC and molecular assessment (62,63). Cytologic smears or fine-needle aspiration specimens, in IMA typically show cohesive clusters of tall columnar tumor cells with prominent intracytoplasmic mucin vacuoles, often in a mucin-rich background. IHC is central to the differential diagnosis of IMA. Thyroid transcription factor-1 (TTF-1; also known as NKX2-1), a classic marker of pulmonary adenocarcinoma, is frequently negative or only weakly positive in IMA; TTF-1 positivity rate is substantially lower than that in NMA (38,64). In contrast, markers more commonly associated with gastrointestinal adenocarcinomas are expressed more frequently in IMA. For example, cytokeratin 20 (CK20) is positive in up to approximately 50% of IMA cases but almost always negative in NMA (<5%). Cytokeratin 7 (CK7), is usually positive, as in other pulmonary adenocarcinomas (17). IMA more often expresses gastric-type mucins, including mucin-5AC (MUC5AC) and MUC5B, rather than MUC1. In a subset of IMA cases, intestinal lineage-associated markers such as MUC2 are also detected, supporting the tendency toward gastrointestinal differentiation (65). In addition, MUC6 expression, reported in a subset of IMA cases, was associated with a favorable prognosis and in vitro, tumor-suppressive effects were demonstrated, supporting a potential role in modulating IMA behavior (66). Notably, hepatocyte nuclear factor 4 alpha (HNF4α), a transcription factor involved in gastrointestinal and hepatocyte differentiation, has been identified as a sensitive marker for IMA, with strong nuclear expression in most cases; therefore assisting in the differential diagnosis from NMA and metastatic mucinous tumors (67). IHC can aid differentiation: IMA is typically TTF-1 negative or weakly positive, CK20 positive in ~50% of cases, and MUC5AC positive, while papillary adenocarcinoma is usually TTF-1 positive, CK20 negative, and MUC5AC negative. Colloid adenocarcinoma often shows a similar immunophenotype to IMA but can be distinguished by its characteristic extracellular mucin pools and absence of lepidic growth. Morphologically, IMA is generally classified as an invasive adenocarcinoma with predominant spread along alveolar walls (lepidic growth), while NMA more often shows solid- or papillary-predominant architecture (68). Importantly, IMA is not invariably purely mucinous; some tumors are mixed mucinous/non-mucinous, containing both invasive components yielding papillary or solid patterns. Pathologically, the mixed type is typically defined by a mucinous component comprising ≥10% of the tumor together with a definite non-mucinous invasive component (69). In a series of 136 IMA cases, 76 were pure mucinous and 23 were mixed mucinous; 29 were classified as mucin-poor despite >10% mucin expression, highlighting substantial intratumoral and intertumoral heterogeneity (17). Clinically, some studies suggest that mixed IMA is associated with worse outcomes, with 5-year survival approaching that of high-grade pure IMA (32). This aligns with observations that pure mucinous IMA often follows a more indolent, lung-confined, course, whereas mixed tumors may behave more aggressively and are more likely to metastasize. Accordingly, the International Association for the Study of Lung Cancer (IASLC) grading system for lung adenocarcinoma recommends grading mixed IMA according to the highest-grade component to improve prognostic stratification (33). In mixed mucinous/NMAs, the mucinous component typically shows low TTF-1 expression and positivity for CK20, MUC5AC, and/or MUC2, consistent with gastrointestinal-type differentiation, while the non-mucinous component retains higher TTF-1 expression and CK7 positivity, with negative CK20 and low MUC5AC expression. This divergence highlights intratumoral heterogeneity and supports the IASLC grading recommendation. Histologically, IMA often appears well differentiated, mucin rich, and cytologically low grade. However, this seemingly benign morphology may mask its invasive potential and recurrence risk, potentially related to STAS and molecular heterogeneity. Accurate morphologic assessment combined with immunophenotyping is essential to distinguish IMA from metastatic gastrointestinal mucinous carcinoma, NMA, and benign mucinous lesions, such as mucinous adenoma or mucinous cystadenoma. We acknowledge that these pathologic features are typically assessed on resected specimens; however, their preoperative identification through imaging or biopsy may inform surgical planning and multidisciplinary decision-making, and their postoperative documentation remains critical for risk stratification and follow-up. For example, colorectal carcinoma metastases are typically CK20-positive and CK7-negative, whereas primary IMA is usually CK7-positive. Although IMA is frequently TTF-1 negative (unlike conventional lung adenocarcinomas), it may express lung-associated mucin markers such as MUC5AC. Once IMA is diagnosed, key pathological features, including STAS and whether the tumor is pure mucinous or mixed, should be reported, to guide surgical planning, risk stratification, and follow-up. STAS STAS is a pathologic pattern in which tumor cells detach from the primary lesion and disseminate within alveolar spaces, forming scattered small clusters in the lung parenchyma beyond the main tumor boundary (7). IMA is associated with a high incidence of STAS; in large resection specimens, the STAS positivity rate was reported to reach 70% (6). Clinically, this is important as airborne tumor cell dissemination beyond surgical margins, increases the risk of postoperative local recurrence, particularly after sublobar resection (wedge resection or segmentectomy) (22,29). There is no current consensus regarding the need for adjuvant therapy for early-stage STAS-positive IMA, but some surgeons advocate a more aggressive surgical approach for high STAS tumors, favoring lobectomy or adequately wide margins (70,71) and enhanced postoperative surveillance. Imaging-pathology correlation IMA imaging heterogeneity reflects underlying histopathologic architecture and variation in mucin production. As described above, IMA is composed predominantly of tall columnar or goblet cells that grow along alveolar walls and secrete abundant extracellular mucin, forming mucin pools. CT shows a nodule or mixed-attenuation lesion when mucin pools are relatively localized and tumor cell density is high. However, with increased mucin production and lower tumor cell density, larger areas of consolidation with attenuation approaching that of fluid (mucin) and sometimes, mucin-filled spaces with entrapped air result in lucencies or honeycomb-like imaging; the “falling snowflake sign” described as scattered solid components against a background of mucin pools (72). In addition, IMA may be biologically heterogeneous, with two distinct IMA cell morphologies; tall columnar (goblet cell) and, less commonly, round cell subtypes. The former is commonly observed in diffuse, lobar pneumonic-type IMA, whereas the round cell subtype is more often associated with solitary-type IMA which may exhibit reduced mucin production, potentially overlapping with non-mucinous lepidic adenocarcinoma (61). These morphologic types may also differ in immunophenotypic and genetic features. The tall columnar cells produce more mucin, forming pools with diffuse consolidation, whereas the round cells are associated with less mucin and localized nodules on imaging (61). Future research should aim to validate the clinical significance of these IMA subgroups within an integrated imaging–molecular framework. Mucin-rich stroma, immune exclusion, and immune heterogeneity Beyond the morphologic consequences, the mucin-rich IMA stroma may substantially shape the tumor immune microenvironment. IMA commonly demonstrates reduced PD-L1 expression and lower CD8+ tumor-infiltrating lymphocyte numbers compared with NMA, supporting an immune-cold phenotype (73,74). Low tumor mutational burden in multifocal IMA and the inferior outcomes of mucinous lung adenocarcinomas treated with immunotherapy-based regimens support limited baseline immunogenicity in a substantial proportion of cases (11). Abundant extracellular mucin may contribute to immune exclusion via physical and biochemical effects on immune-cell trafficking, tumor-immune cell interactions, and local glycan-associated signaling (75,76). Mucin-associated alterations may also affect intratumoral distribution of therapeutic agents. Although a direct causal association between mucin burden and resistance to PD-(L)1 blockade has not yet been demonstrated in IMA, the mucin-rich microenvironment remains a biologically plausible contributor to immune exclusion and a potential predictor of immunotherapy resistance. Immune heterogeneity is likely to be relevant in IMA. Pure mucinous and mixed mucinous/non-mucinous tumors differ in morphology, differentiation programs, and molecular profiles (15,17), which may be accompanied by variation in immune composition. Spatial differences between dominant lesions and aerogenously disseminated foci, the relative distribution of mucin pools, malignant epithelial cells, myeloid populations, and effector lymphocytes; all remain poorly characterized in IMA. Multi-region sampling and spatially resolved profiling will be required to define immune states and to determine their predictive relevance for systemic therapy (77). Molecular biologic features and oncogenic mechanisms Driver mutation landscape The molecular identity of IMA is anchored by frequent KRAS mutations and recurrent NRG1 fusions. KRAS is the most common driver alteration in IMA, reported in 50–80% of cases, most often involving codon 12 substitutions such as G12D, G12V, and G12C (8,78). This high prevalence supports the recognition of IMA as a molecularly distinct subtype of lung adenocarcinoma and provides a major rationale for separating IMA from conventional NMA in translational studies. Notably, IMA is enriched for several rare gene fusions; NRG1 fusions being the most prominent. NRG1 fusions (e.g., CD74-NRG1) are rare in non-small cell lung cancer (NSCLC) overall (<1%) but are reportedly detected in ~7–30% of IMA (9,10,79). NRG1 fusions occur predominantly in never-smokers or light smokers and are often mutually exclusive with KRAS mutations. Mechanistically, the fusion protein exhibits NRG1 ligand-like activity, activates ERBB2/ERBB3 receptors, and drives downstream mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K) signaling (80,81), ultimately converging on RAS-MAPK signaling like KRAS mutations. Additional fusions reported in IMA, include ALK, proto-oncogene tyrosine-protein kinase ROS (ROS1), and neurotropic receptor kinase 1 (NTRK1)/3, although they are considerably less frequent than NRG1 fusions (9,82-84). In particular, adenocarcinomas showing ALK- and ROS1-rearrangement may show extensive mucin production, closely resembling classic IMA on limited histologic material. Therefore, mucin-producing adenocarcinomas harboring ALK or ROS1 rearrangements are best regarded as important diagnostic mimics or overlapping mucinous adenocarcinoma phenotypes, rather than automatically being classified as core molecular subsets of classic IMA, and final classification should integrate radiologic distribution, growth pattern, mucinous differentiation, immunophenotype, and molecular findings. The clinical implications of these rearrangements remain important. In a retrospective dual-center cohort of resected IMA, ALK fusion protein expression was associated with a lower recurrence rate (20.8% vs. 40.6%) and independently with a favorable postoperative survival (83). However, the prognostic significance of ALK positivity in resectable NMA has been inconsistent; some reports indicate a higher recurrence risk in ALK-positive patients with completely resected stage I disease, while others describe favorable long-term outcomes following surgical resection (85,86). HER2 -also known as Erbb-b2 receptor kinase protein (ERBB2)-mutations are detected in a minority of IMA cases, including exon 20 insertions (10,14). B-rapidly accelerated fibrosarcoma (BRAF) mutations are occasionally identified (~1–3%) but are more often non-classical, non-V600E variants (87). Compared with NMA, IMA shows a different balance of oncogenic drivers. EGFR mutations, which are common therapeutic targets in NMA, are detected in only a subset of IMA and are generally less frequent than in non-mucinous tumors (35,88). A stepwise decrease in EGFR mutation frequency from non-IMA to mixed IMA and then to pure IMA (72.0% vs. 40.0% vs. 23.1%; P=0.002) has previously been demonstrated (89). This difference may help explain why therapeutic strategies developed for EGFR-mutant NMA cannot be directly extrapolated to most patients with IMA. Overall, the molecular landscape of IMA is best understood as a layered, diagnostic and translational framework. KRAS mutations and NRG1 fusions represent the principal molecular hallmarks of classic IMA. ALK- and ROS1-rearranged mucin-producing adenocarcinomas should be recognized as important diagnostic mimics or overlapping mucinous adenocarcinoma phenotypes, particularly when classification relies on limited biopsy material. ERBB2/HER2, BRAF, and NTRK alterations are less frequent but potentially actionable findings. This framework is clinically important because it links histologic diagnosis, tissue requirements for molecular testing, and therapeutic stratification. Signaling pathways and transcriptional regulation Although KRAS mutations and ALK or NRG1 fusions are distinct genetic events, they can converge functionally on the RAS-RAF-MEK-ERK (MAPK) pathway (80,90). NRG1 fusion proteins act as ligand mimetics that engage ERBB3/ERBB4 and promote ERBB2-containing heterodimerization activating RAS-dependent RAF-MEK-MAPK signaling and the PI3K-AKT-mTOR cascade (Figure 2). At the nuclear level, ERK/MAPK signaling regulates transcriptional responses through factors including ELK-1 and CREB (91,92). Through these nuclear effectors, MAPK signaling regulates gene programs involved in cell-cycle progression, proliferation, survival, and cellular adaptation. In IMA, recurrent MAPK activation driven by KRAS mutations or NRG1 fusion-mediated ERBB signaling may sustain transcriptional programs that support tumor growth and persistence. The high prevalence of KRAS mutations and NRG1 fusions suggests that IMA initiation and maintenance may depend heavily on MAPK signaling, emphasizing the importance of this pathway as a potential therapeutic target. However, as direct RAS targeting remains challenging, current strategies typically target downstream effectors such as MEK (93). Beyond growth factor-related signaling, IMA also shows a distinct regulatory network governing mucin production. Lung developmental transcription factors and goblet cell-like differentiation programs are closely linked to the IMA phenotype. Loss of NK homeobox 1 (NKX2-1) also known as TTF-1, has been proposed as a prerequisite for mucinous adenocarcinoma development in a murine model (94). Mucin differentiation factors such as forkhead box A2 (FOXA2) and SAM pointed domain-containing Ets transcription factor (SPDEF) are critical for establishing the mucinous phenotype (74,95). Tomoshige and colleagues demonstrated that FOXA2 drives expression of mucin-related genes (e.g., SPDEF and MUC5AC) in KRAS^G12D-mutant lung epithelium, producing a tumor phenotype that resembles human IMA. Mechanistically, FOXA2 binds and activates the MUC5AC enhancer while upregulating the key mucin transcription factor SPDEF indicating that the FOXA2-KRAS combination is a functional driver of IMA development. The mucinous phenotype may therefore, actively contribute to tumor initiation and dissemination of IMA rather than being a passive byproduct (96). Mucin may function as both a phenotypic marker and a driver; activation of mucin cell differentiation programs may confer survival and metastatic advantages. The schematic depicts the oncogenic signaling cascade driven by NRG1 fusion in IMA. Acting as aberrant ligands, NRG1 fusions bind to ERBB3 or ERBB4 at the plasma membrane. This interaction induces heterodimerization with ERBB2, thereby activating the ERBB2-ERBB3/ERBB4 kinase complex triggering two primary downstream oncogenic pathways: the RAS-RAF-MEK-MAPK cascade and the PI3K-AKT-mTOR axis. PI3K generates the second messenger PIP3, which recruits AKT to activate mTOR-mediated cellular growth and metabolism. Concurrently, MAPK signaling regulates nuclear transcription factors, including ELK-1 and CREB, thereby modulating transcriptional programs associated with promotion of cell proliferation and survival, and cellular adaptation (mucinous differentiation). Collectively, NRG1 fusions activate MAPK and PI3K signaling via the ERBB2-ERBB3 axis, converging with KRAS mutations at downstream effector nodes. This convergence underscores the critical role of the RAS-RAF-MAPK axis in the initiation and maintenance of IMA. IMA, invasive mucinous adenocarcinoma. In summary, IMA exhibits a distinct molecular landscape from other lung cancers, characterized by KRAS mutations and fusion events, activation of mucin differentiation programs, and a mucin-rich, immunologically inert, tumor microenvironment. These features provide diagnostic and classification information while offering potential strategies for the development of targeted therapy including indirect inhibition of KRAS signaling, disruption of the mucin barrier to improve drug delivery and immune cell access, and blockade of the NRG1-ERBB axis. Subsequent sections discuss how these molecular features influence treatment decisions and practical challenges in clinical management. Treatment response patterns and challenges in precision Surgical management Surgery remains the preferred option for early-stage, localized IMA. However, the multifocality and aerogenous spread common in IMA may complicate complete resection. Sublobar resection (e.g., wedge resection or anatomic segmentectomy) is not inferior to lobectomy in survival outcomes for solitary, small (≤2 cm) peripheral IMA. The 5-year recurrence-free survival (RFS) was 98.9% after wedge resection or segmentectomy and 97.0% after lobectomy, in a retrospective study of 279 patients with clinical stage IA peripheral IMA (≤2 cm), with no significant difference between groups after propensity score matching (28). The importance of adequate surgical margins (≥2 cm or greater than the tumor diameter) was emphasized to reduce the risk of residual microscopic disease. In multifocal IMA or diffuse pneumonic-type disease, all microscopic foci may not be removed, even by anatomic resection, since lesions often represent intrapulmonary dissemination or metastasis (69). In such cases, surgical strategies must be individualized, based on lesion distribution and pulmonary reserve. If preoperative imaging shows multiple suspicious mucinous foci in different ipsilateral lobes, staged resections at multiple sites, combined sublobar, or multisegment resections, or, in selected cases, a more extensive lobectomy to reduce local tumor burden, may be considered. However, previous studies suggest that pneumonic-type IMA is more aggressive, with higher postoperative recurrence and worse survival than localized or nodular IMA, which may limit the incremental benefit of more extensive resection (37). Whether STAS-positive IMA warrants wider margins or adjuvant therapy remains uncertain (97), with no current guidelines specifying extent of resection in IMA. Multidisciplinary decisions should integrate disease distribution, pulmonary function and patients’ general condition. In summary, surgery yields favorable outcomes in localized IMA, whereas curative resection is often difficult in multifocal or diffuse disease. Response to chemotherapy and radiotherapy IMA is generally less sensitive to conventional chemotherapy. In clinical practice, platinum-based doublet therapy is less effective in advanced IMA than in NMA (98,99). A retrospective study of platinum-based chemotherapy in IMA reported an ORR of 25.7% and a median PFS of 8.1 months, indicating a modest response (26). Pemetrexed plus platinum typically yields a median PFS of ~4.9 months in unselected populations (100). Therefore, PFS in IMA is not necessarily worse. However, the relatively low ORR (potentially due to low IMA cell proliferation and/or reduced intratumoral drug penetration due to abundant mucin) and tumor biological heterogeneity underscore the need for better stratification and treatment selection. However, direct evidence is limited and further clinical trials are needed. No IMA-specific chemotherapy regimen has been established; clinical practice generally follows NSCLC paradigms, most commonly pemetrexed plus platinum. Isolated case reports have explored gastrointestinal-type chemotherapy regimens, such as oxaliplatin plus capecitabine (XELOX/CAPOX), in selected patients with mucin-rich or gastrointestinal-like phenotypes (26). However, these reports should be regarded as anecdotal and hypothesis-generating rather than evidence sufficient to support routine clinical use. At present, XELOX/CAPOX or similar regimens should not be considered standard treatment for pulmonary IMA, and their use, if considered at all, should be limited to highly selected circumstances after multidisciplinary discussion, or within prospective clinical studies. Radiotherapy is typically used for palliation in advanced IMA, or as an adjunct after incomplete resection, or in patients at high risk of local recurrence, as in advanced NSCLC generally. Unfortunately, evidence specific to mucinous adenocarcinoma remains scarce. Targeted therapy The therapeutic implications of molecular alterations in IMA should be interpreted in the context of its distinct molecular landscape described above. To avoid redundancy, this section focuses on the clinical relevance of these alterations rather than reiterating their biological mechanisms. Compared with NMA, IMA has a distinct spectrum of driver alterations with a lower prevalence of canonical actionable drivers such as EGFR mutations (19,34,78). Accordingly, only a small subset of IMA patients is expected to benefit from EGFR tyrosine kinase inhibitors (TKIs) (35). By contrast, although KRAS mutations are frequent, effective targeted options have historically been limited. The development of allele-specific inhibitors, such as the ^G12C inhibitors sotorasib and adagrasib, has transformed the treatment landscape for KRAS-mutant NSCLC (11). However, the G12C allele accounts for a relatively small fraction of KRAS mutations in IMA (often <10% in Asian cohorts) (8,36), limiting the population eligible for these agents. Furthermore, emerging real-world evidence suggests that while active, the efficacy of KRAS G12C inhibitors can be variable (101). Recent investigations into the molecular features associated with response have suggested that mucinous differentiation may be one factor influencing outcomes, underscoring the need for subtype-specific analyses (30). ALK rearrangements are uncommon in IMA. When present, management generally follows standard ALK-positive NSCLC algorithms using ALK TKIs (e.g., crizotinib, alectinib). Case reports and small series suggest that ALK-positive IMA can achieve responses comparable to those in NMA (31). For ROS1 fusion-positive IMA, ROS1 TKIs may be considered; limited data suggest improved overall survival in patients receiving targeted therapy (102). NRG1 fusions, promoting ligand-mediated activation of the ERBB3-ERBB2 axis and activating downstream oncogenic signaling, are a distinctive and potentially actionable target in IMA. Currently, multiple clinical trials are evaluating targeted therapeutic strategies for NRG1 fusion-positive tumors. One approach uses pan-ERBB inhibitors such as afatinib, which covalently inhibits ERBB-family receptors and may suppress NRG1 fusion-driven signaling (79,103). However, in a phase I trial (NCT01966445), an NRG1 fusion-positive patient with IMA did not achieve an objective response to afatinib (104). By contrast, HER2/HER3 bispecific antibodies such as zenocutuzumab (MCLA-128) bind HER2 and HER3, inhibit NRG1 fusion-mediated HER3 activation, and recruit immune effector functions. Early trials in NRG1 fusion-positive solid tumors, including IMA, have shown clinical activity with tumor shrinkage and symptomatic improvement in some patients (105). Beyond canonical oncogenic drivers, lineage-associated biomarkers may also have therapeutic relevance in IMA which often exhibits gastric-type mucinous differentiation, characterized by low or absent TTF-1 expression, relatively frequent CK20 expression, and expression of gastric-type mucins such as MUC5AC and MUC5B (38,64-67). These features provide a rationale for evaluating Claudin 18.2, a claudin-family, tight-junction transmembrane protein that may be aberrantly expressed during malignant transformation in gastric, pancreatic, esophageal, colorectal, and lung adenocarcinomas (106). Studies suggest that Claudin 18.2 is expressed at relatively high rates in IMA (~60–80%) (107,108). In a cohort of 84 IMA cases, 76.2% were Claudin 18.2-positive by IHC, and 46.4% met typical eligibility criteria for anti-Claudin 18.2 antibody trials (≥75% of tumor cells with ≥2+ staining). Higher Claudin 18.2 expression was associated with smaller tumors, less pleural invasion, and earlier N stage, suggesting that Claudin 18.2-high IMA may be less invasive. Although Claudin 18.2 expression shows no clear prognostic impact, its high positivity in IMA suggests that Claudin 18.2-directed therapies (e.g., monoclonal antibodies or CAR T-cell approaches) may offer an option for patients lacking conventional actionable targets (109). Table 2 summarizes molecular alterations and potential therapeutic targets in IMA. Table 2Molecular alterations and potential therapeutic targets in IMAAlteration/biomarkerMolecular alterationTherapeutic implicationsKRAS mutationMost frequent driver in IMA, present in roughly 50–80% of cases. This rate is much higher than non-mucinous lung adenocarcinoma (<15%). The mutations usually involve KRAS G12 codon (e.g., G12D, G12V, G12C) (8,78)Direct KRAS-targeted therapies are limited. KRAS^G12C-specific inhibitors (e.g., sotorasib) are available but only benefit the subset of IMA patients with G12C mutations (often <10% of KRAS-mutant IMA) (8,36)NRG1 gene fusionA characteristic alteration enriched in IMA. NRG1 fusions (e.g., CD74-NRG1) are detected in ~7–30% of IMA, whereas they are exceedingly rare (<1%) in lung adenocarcinoma overall (9,10,79)No targeted therapy is yet approved for NRG1-rearranged tumors. Clinical trials are exploring pan-ERBB inhibitors (e.g., afatinib) and HER2/HER3 bispecific antibodies (e.g., zenocutuzumab in patients with NRG1 fusion-positive IMA, with early signs of partial tumor responses in some cases (80,103-105)Claudin 18.2 overexpressionClaudin 18.2, a tight junction protein, is highly expressed in IMA (107,108). Studies report about 46% of cases meet high-expression criteria (≥75% tumor cells with ≥2+ staining) for clinical trials of targeted therapy (109)Claudin 18.2 is an emerging target; monoclonal antibodies and CAR-T cell therapies against Claudin 18.2 are under investigation and may offer new treatment options for IMA patients lacking other actionable targets (108,109)EGFR mutationRare in IMA (frequency generally <5%), whereas EGFR mutations are common in non-mucinous lung adenocarcinoma (8-10,35)Because classical EGFR mutations are infrequent, only a small fraction of IMA patients respond to EGFR TKIs (35,78)ALK fusionUncommon in classic IMA, but ALK-rearranged adenocarcinomas may show extensive mucin production and mimic IMA, particularly in small biopsy specimens. EML4-ALK is a more common variant (9,82)ALK-rearranged IMA responds well to ALK TKIs (e.g., crizotinib, alectinib), with clinical outcomes comparable to ALK-positive non-mucinous lung cancers (31)ROS1 fusionDetected in a small subset of IMA (102)ROS1-rearranged IMA can be treated with ROS1 inhibitors (e.g., crizotinib, entrectinib). Limited data suggest patients with ROS1-positive IMA have improved outcomes on targeted therapy—one series noted prolonged survival in ROS1-fusion patients who received TKIs (102)Other infrequent alterationsHER2 (ERBB2) mutations are found in a minority of IMAs (including exon 20 insertions) (10,14). BRAF mutations occur in ~1–3% of cases, typically non-V600E variants (87). Rare fusions involving NTRK1/3 have also been reported (9)Targeted agents exist for some of these alterations (e.g., HER2 inhibitors like trastuzumab-derivatives, BRAF/MEK inhibitors for BRAF-mutant tumors, TRK inhibitors for NTRK fusions). However, due to the low incidence of HER2, BRAF, or NTRK alterations in IMA, such targeted therapies would only apply to very few patients (9,10,14,87)CAR-T, chimeric antigen receptor T cell therapy; IMA, invasive mucinous adenocarcinoma; TKI, tyrosine kinase inhibitor. Molecular alterations and potential therapeutic targets in IMA CAR-T, chimeric antigen receptor T cell therapy; IMA, invasive mucinous adenocarcinoma; TKI, tyrosine kinase inhibitor. Tumor immune microenvironment and immunotherapy Clinical activity of immune checkpoint inhibitors (ICIs) in IMA remains incompletely defined. Retrospective series suggest that mucinous lung adenocarcinoma and KRAS-mutant IMA may derive less benefit from ICI-based therapy than non-mucinous counterparts (11,27). However, the available studies are limited by small IMA-specific sample sizes, treatment heterogeneity, and incomplete integration of PD-L1, tumor mutational burden, and co-mutation data. Histology alone should therefore not be used to determine eligibility for immunotherapy. Immune heterogeneity may partly explain variable treatment outcomes. Mucin burden, histologic composition, spatial distribution of disease, and the balance between lymphoid and myeloid populations may differ across lesions and within individual tumors. Small biopsies may consequently provide an incomplete representation of the immune milieu, particularly in multifocal or pneumonic-type disease. Prospective studies should incorporate standardized PD-L1 assessment, quantitative characterization of lymphoid and myeloid populations, and spatial profiling of mucin-rich tumor regions. The high prevalence of KRAS alterations in IMA also raises the potential importance of co-occurring genomic events. In KRAS-mutant lung adenocarcinoma, STK11/LKB1 and KEAP1 alterations have been associated with distinct immune phenotypes, reduced responsiveness to PD-(L)1 blockade, and inferior outcomes with immunotherapy (110,111). These data are derived predominantly from unselected or non-mucinous lung adenocarcinoma cohorts and cannot be directly extrapolated to pathologically defined IMA. STK11 and KEAP1 should therefore be regarded as exploratory stratification variables in IMA rather than validated IMA-specific biomarkers of immunotherapy resistance. Current evidence supports an individualized approach to immunotherapy in advanced IMA, integrating standard clinicopathologic variables, PD-L1 expression, tumor mutational burden, actionable oncogenic drivers, and relevant co-mutation profiles. In STK11- or KEAP1-altered NSCLC, dual CTLA4/PD-L1 blockade combined with chemotherapy has shown activity that may partially mitigate resistance observed with PD-(L)1 inhibition alone; whether this observation applies to IMA remains unknown (112). Dedicated prospective IMA cohorts are needed to distinguish prognostic immune features from biomarkers that genuinely predict benefit from specific immunotherapy-based regimens. Current controversies, knowledge gaps, and future directions Although substantial progress has been made in understanding IMA, important questions remain unresolved and continue to fuel debate. Should IMA be considered an independent disease entity? In the current WHO classification, IMA is categorized as a variant of lung adenocarcinoma. As molecular and clinical distinctions become clearer, some investigators argue that IMA merits recognition as an independent entity. Prognosis and treatment responses differ from those of conventional lung adenocarcinoma, suggesting that a uniform NSCLC management paradigm may be suboptimal for IMA (26,61). Accordingly, IMA-specific staging, grading, and treatment guidance may improve outcomes—for example, via a dedicated grading system or an IMA-tailored TNM framework (25). Future molecular studies should clarify whether IMA and NMA form a continuum or represent distinct evolutionary lineages. Should IMA be considered an independent disease entity? In the current WHO classification, IMA is categorized as a variant of lung adenocarcinoma. As molecular and clinical distinctions become clearer, some investigators argue that IMA merits recognition as an independent entity. Prognosis and treatment responses differ from those of conventional lung adenocarcinoma, suggesting that a uniform NSCLC management paradigm may be suboptimal for IMA (26,61). Accordingly, IMA-specific staging, grading, and treatment guidance may improve outcomes—for example, via a dedicated grading system or an IMA-tailored TNM framework (25). Future molecular studies should clarify whether IMA and NMA form a continuum or represent distinct evolutionary lineages. The origin of multifocal IMA: intrapulmonary metastasis versus multicentric development. Multifocal disease is among the most challenging clinical presentations. Patients with IMA often present with multiple synchronous mucinous lesions in one or both lungs. These lesions often share similar morphology and immunophenotypes, complicating distinction between intrapulmonary spread from a single primary tumor and multiple independent primaries arising in a permissive pulmonary milieu. The traditional view favors a single clonal origin, with aerogenous spread proposed to account for multifocal IMA (7). By contrast, other studies propose permissive “soil” factors that predispose bronchial and alveolar epithelium to mucinous transdifferentiation, enabling independent tumor emergence across lung segments (38). Contemporary sequencing enables clonality assessment in multifocal disease. Shared driver mutations and concordant mutational profiles support a clonal metastatic origin, whereas discordant drivers across lesions favor multicentric primaries. Both patterns have been reported in small case series (23). Large-scale studies with systematic, multi-region sequencing are required, as the distinction directly affects staging and treatment decisions. The origin of multifocal IMA: intrapulmonary metastasis versus multicentric development. Multifocal disease is among the most challenging clinical presentations. Patients with IMA often present with multiple synchronous mucinous lesions in one or both lungs. These lesions often share similar morphology and immunophenotypes, complicating distinction between intrapulmonary spread from a single primary tumor and multiple independent primaries arising in a permissive pulmonary milieu. The traditional view favors a single clonal origin, with aerogenous spread proposed to account for multifocal IMA (7). By contrast, other studies propose permissive “soil” factors that predispose bronchial and alveolar epithelium to mucinous transdifferentiation, enabling independent tumor emergence across lung segments (38). Contemporary sequencing enables clonality assessment in multifocal disease. Shared driver mutations and concordant mutational profiles support a clonal metastatic origin, whereas discordant drivers across lesions favor multicentric primaries. Both patterns have been reported in small case series (23). Large-scale studies with systematic, multi-region sequencing are required, as the distinction directly affects staging and treatment decisions. Future research priorities Given the distinctive biology and the limited evidence base, future research in IMA is needed on several fronts. First, single-cell sequencing and spatial omics should be more widely applied to define tumor cell states, mucin-associated niches, and immune composition in IMA. Spatial transcriptomics integrated with multiplex IHC has begun to delineate subtype-specific programs and immunosuppressive microenvironments in lung adenocarcinoma (77). Analogous analyses in IMA could clarify intratumoral heterogeneity and transcriptional reprogramming during aerogenous spread. Second, integrated imaging-molecular modeling warrants further development. Radiogenomic approaches linking CT/PET phenotypes to genomic and metabolic profiles could enable noninvasive prediction of IMA subtypes and high-risk features. Novel PET ligands, for example targeting mucin or specific receptors, need to be studied in IMA. Third, prospective cohorts and clinical trials are essential to address key evidence gaps, since most available data comes from retrospective analyses. Multicenter IMA-specific registries and trials that stratify patients by IMA status, or enroll IMA as a dedicated cohort, are needed-particularly for biology-driven strategies (e.g., anti-HER3 in NRG1 fusion-positive IMA and Claudin 18.2-directed approaches). In parallel, genomic and radiologic criteria for distinguishing intrapulmonary metastasis from multicentric primaries should be standardized, because this distinction affects TNM staging and eligibility for local therapy. Future research priorities Given the distinctive biology and the limited evidence base, future research in IMA is needed on several fronts. First, single-cell sequencing and spatial omics should be more widely applied to define tumor cell states, mucin-associated niches, and immune composition in IMA. Spatial transcriptomics integrated with multiplex IHC has begun to delineate subtype-specific programs and immunosuppressive microenvironments in lung adenocarcinoma (77). Analogous analyses in IMA could clarify intratumoral heterogeneity and transcriptional reprogramming during aerogenous spread. Second, integrated imaging-molecular modeling warrants further development. Radiogenomic approaches linking CT/PET phenotypes to genomic and metabolic profiles could enable noninvasive prediction of IMA subtypes and high-risk features. Novel PET ligands, for example targeting mucin or specific receptors, need to be studied in IMA. Third, prospective cohorts and clinical trials are essential to address key evidence gaps, since most available data comes from retrospective analyses. Multicenter IMA-specific registries and trials that stratify patients by IMA status, or enroll IMA as a dedicated cohort, are needed-particularly for biology-driven strategies (e.g., anti-HER3 in NRG1 fusion-positive IMA and Claudin 18.2-directed approaches). In parallel, genomic and radiologic criteria for distinguishing intrapulmonary metastasis from multicentric primaries should be standardized, because this distinction affects TNM staging and eligibility for local therapy. Conclusions IMA is generally accepted as a distinct subtype of lung adenocarcinoma with unique biological and clinical features. It is characterized by frequent multifocal/aerogenous spread, low FDG avidity, mucinous histology, and a genomic landscape enriched for KRAS mutations and oncogenic fusions, with canonical EGFR alterations being uncommon. IMA commonly presents as atypical pneumonia, therefore, in antibiotic-refractory pneumonic-type consolidation, early tissue confirmation and multidisciplinary integration of imaging, pathology, and comprehensive molecular profiling are essential. Surgery can be curative for localized disease; however, effective systemic options for advanced IMA remain limited. Future progress will likely rely on biomarker-driven trials targeting IMA-enriched vulnerabilities, including NRG1-ERBB signaling and Claudin 18.2, together with a more precise definition of the immune phenotypes associated with mucin-rich disease. Integrating mucin burden, immune-cell composition, PD-L1 expression, and co-occurring genomic alterations may identify clinically meaningful subgroups with distinct therapeutic vulnerabilities. Prospective registries, radiogenomic approaches, spatial multi-omics studies, and IMA-specific immunotherapy cohorts are needed to refine staging, grading, and subtype-tailored precision oncology. Supplementary The article’s supplementary files as Acknowledgments None. Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Footnotes Funding: None. Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-2026-0430/coif). The authors have no conflicts of interest to declare. References Available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-2026-0430/prf Supplementary Materials The article’s supplementary files as